Medicalisation

Diseases are partly discovered and partly defined — and the definitions are written by committees. When a guideline panel lowers a diagnostic threshold, invents a pre-disease, or converts a risk factor into a condition, millions of people become patients overnight without their bodies changing at all: the 2017 US redefinition of hypertension to 130/80 reclassified roughly 31 million American adults in a day; prediabetes under the broadest criteria captures around a third of the adult population, though only a small percentage progress to diabetes each year; osteopenia was created at a 1992 consensus meeting as a statistical category and became a prescribing indication. Each individual expansion had defensible arguments; the aggregate pattern — boundaries that move almost exclusively outward — is the phenomenon medicalisation names.

The reason boundaries move outward is that expansion has a business model and contraction does not. The canonical cases are documented in marketing plans, not inferred: 'Low T' converted male ageing into an androgen deficiency market (see the testosterone hub); social anxiety disorder was promoted to the American public in a nine-figure campaign timed to a drug's approval for it; female sexual desire disorder acquired a drug of marginal efficacy after a manufacturer-funded advocacy campaign lobbied regulators on equity grounds. Systematic studies find guideline and diagnostic-definition panels are frequently majority-populated by members with financial ties to companies selling the relevant treatments, and panels that widen definitions rarely publish the harm-benefit analysis of doing so. None of this requires conspiracy — just aligned incentives compounding annually.

A diagnosis is an intervention with side effects. Labelling effects are measurable — people told they have hypertension show increased absenteeism and lower wellbeing independent of blood pressure; a pre-disease label converts a healthy person into an anxious patient with a surveillance schedule; and every expansion dilutes treatment benefit, because people near the new, milder boundary gain less from treatment while carrying the same side-effect risks, worsening the population number-needed-to-treat. Downstream sit the cascades: monitoring, incidental findings, polypharmacy, and the diversion of clinical attention from the severely ill to the newly labelled — the low-value-care hub quantifies that end of the pipeline.

The critique collapses into its own failure mode when it becomes disease denial. Endometriosis carries diagnostic delays approaching a decade; depression and psychosis go untreated at scale in much of the world; ME/CFS and long COVID patients spent years fighting for recognition against exactly the 'medicalising ordinary life' rhetoric this hub describes; and historical medicine dismissed real suffering — especially women's — as hysteria for centuries. Medicalisation and underdiagnosis coexist, often in the same health system: the worried well are over-labelled while the seriously ill queue. The honest position holds both, and treats 'is this expansion evidence-based?' as an empirical question per condition, not an ideology.

A working toolkit for each newly announced condition or widened definition: Who wrote the definition, and what are their declared interests? What absolute benefit do the newly included patients gain from treatment — is there trial evidence in the milder population, or extrapolation from the severe one? What happens to the number-needed-to-treat at the new boundary? Is a treatment being launched alongside the definition? Would the people being recruited consider themselves ill without the announcement? And is anyone publishing the case against? Definitions that survive this audit exist — the expansions that found genuinely undertreated disease — and the audit is what separates them from the marketing.

For patients: a new label deserves the same scrutiny as a new drug — ask what the diagnosis changes about treatment, what your absolute risk actually is, and what watchful waiting would cost; declining a pre-disease label is often a legitimate clinical option. For clinicians: diagnose to help, not to file — the question is whether the label leads to net-beneficial action for this patient. For readers of health news: condition-awareness campaigns are frequently product launches wearing public-health clothing, and the tell is a definition, a celebrity, and a branded treatment arriving together. Disease is real; the boundary is a decision — audit the decision.